Duality Biotherapeutics Inc (9606) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Duality Biotherapeutics Inc stock HK$34.27, price HK$102, that is 66.5% below the price, quality 37 out of 100. Rating: strongly overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Duality Biotherapeutics Inc
9606 · HKFar too expensive (fair value 67% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.
How to read this chart
19‑month range HK$94.60 – HK$510.00 · fair‑value band HK$30.09 – HK$40.81 · the HK$102.20 price screens above the HK$34.27 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.
Every Wednesday you see whether Duality Biotherapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally.
Show moreShow less
The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; and BeOne to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC. The company was incorporated in 2019 and is headquartered in Shanghai, China.
Stock analysis
Duality Biotherapeutics Inc (9606) currently trades at HK$102.20, while our model-based Fair Value estimate is HK$34.27, 67% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of HK$45.35 per share, and 0 of the 7 models we run sit above the HK$102.20 price.
Bear case: the Asset-Based group reads lowest at HK$29.99, and 7 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$30.09 (bear) to HK$40.81 (bull), the price of HK$102.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Duality Biotherapeutics Inc reported revenue of 1.8B CNY in FY2025 versus 1.6M CNY in FY2022, a compound +940.8%/yr. Reported net income was −2.5B CNY in FY2025.
Key figures
Market cap HK$9.5B (≈ $1.2B) Small · P/S ratio 16.2 · Net margin −140% · Return on equity −65.9% · Return on assets (EBIT) −11.8% (4-year average) · Operating margin −418% · Revenue (TTM) 842M CNY · Revenue growth (YoY) −82.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 72% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −67%, 9606 screens richer than that median.
Fair Value models
All 7 models by family
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Compare Duality Biotherapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Fair value gap by industry
- Return on assets by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $955.47 | $1,275 | +33% | vs 9606 |
| Vertex Pharmaceuticals Incorporated VRTX | $538.60 | $592.46 | +10% | vs 9606 |
| Samsung Biologics Co 207940 | 1,411,000 KRW | 1,552,100 KRW | +10% | vs 9606 |
| Genmab A/S GMAB | kr 3,448 | kr 3,793 | +10% | vs 9606 |
| argenx SE ARGX | $960.04 | $908.40 | −5% | vs 9606 |
| CSL Limited CSL | A$202.52 | A$185.51 | −8% | vs 9606 |
| Moderna, Inc MRNA | $223.37 | $139.99 | −37% | vs 9606 |
| Revolution Medicines, Inc RVMD | $172.29 | $88.78 | −48% | vs 9606 |
| Celltrion, Inc 068270 | 214,000 KRW | 74,945 KRW | −65% | vs 9606 |
| Royalty Pharma plc RPRX | $69.31 | $19.01 | −73% | vs 9606 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Duality Biotherapeutics Inc (9606) overvalued or undervalued?
What is the fair value of 9606?
What is the quality score of 9606?
What is the price target for Duality Biotherapeutics Inc (9606)?
What is the Duality Biotherapeutics Inc stock forecast for 2026?
What is the revenue of Duality Biotherapeutics Inc (9606)?
What growth is priced into Duality Biotherapeutics Inc (9606)?
What discount rate (WACC) does the fair value of 9606 use?
What is a reverse DCF?
How much growth has Duality Biotherapeutics Inc (9606) delivered so far?
How fast is the sector of Duality Biotherapeutics Inc (9606) growing?
What is the free cash flow yield of Duality Biotherapeutics Inc (9606)?
What is the intrinsic value of Duality Biotherapeutics Inc (9606)?
Is Duality Biotherapeutics Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 9606?
How much is Duality Biotherapeutics Inc worth?
What do the bullish and bearish scenarios say about 9606?
How solid is the balance sheet of Duality Biotherapeutics Inc (9606)?
How far is 9606 from its 52-week high?
Which stocks are comparable to Duality Biotherapeutics Inc?
Is Duality Biotherapeutics Inc stock attractive at the current price?
How is the fair value of 9606 calculated?
Is it still worth investing in stocks now?
What is the share price of Duality Biotherapeutics Inc (9606)?
What should I pay attention to with Duality Biotherapeutics Inc right now?
Key figures of Duality Biotherapeutics Inc
How large is the market capitalisation of Duality Biotherapeutics Inc (9606)?
What is the P/S ratio of Duality Biotherapeutics Inc (9606)?
What is the net margin of Duality Biotherapeutics Inc (9606)?
What is the return on equity of Duality Biotherapeutics Inc (9606)?
What is the EBIT return on assets of Duality Biotherapeutics Inc (9606)?
What is the operating margin of Duality Biotherapeutics Inc (9606)?
How fast is revenue growing at Duality Biotherapeutics Inc (9606)?
How much net cash does Duality Biotherapeutics Inc (9606) hold?
Watch Duality Biotherapeutics Inc in the live analysis
One click puts Duality Biotherapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.